Original Post from GeneomeWeb
NEW YORK (360Dx) – NeoGenomics on Thursday priced its previously announced public offering of 9.8 million shares of its common stock at $12.75 per share.
Gross proceed from the offering are expected to be approximately $125 million.
NeoGenomics has granted the underwriters a 30-day option to purchase up to 1.47 million additional shares of common stock at the public offering price, less underwriting discounts and commissions.
The offering is expected to close on or about Aug. 14, the company said.
William Blair and Leerink Partners are acting as joint book-running managers for the offering. Craig-Hallum Capital Group, Stephens, First Analysis Securities, Janney Montgomery Scott, and The Benchmark Company are acting as comanagers.
NeoGemonics intends to use the net proceeds from the offering to fund the growth of the business, including the acquisition of, and investment in, businesses that it believes will enhance the value of NeoGenomics. NeoGenomics may also use proceeds for working capital and for general corporate purposes including the repayment of existing indebtedness.